ProFarma Seeks $6 Million Series A to Advance Neuroprotective Pipeline
Remis Bistras, CEO of ProFarma, lays out the company’s plan to improve the delivery and effective life of drugs that strengthen neuroprotectiveness in retina ganglion cells. The company has committed $2 million to date for animal and preclinical testing and has designs on filing its first IND within 15 to 18 months. It ultimately hopes to develop treatments for NAION, retinitis pigmentosa, and glaucoma.